IDRA News and Press, Idera Pharmaceuticals Inc. From 06/02/20

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of  ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate tilsotolimod ...

EXTON, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) via the filing of...

Idera Pharmaceuticals (NASDAQ: IDRA ): Q1 Non-GAAP EPS of -$0.43; GAAP EPS of -$0.22 beats by $0.14 . Cash and equivalents of $33.5M. Press Release More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

EXTON, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2020. “I’m proud of what Idera has acco...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

EXTON, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9...

Idera Pharmaceuticals ( IDRA -2.4% ) announces final results from a Phase 1/2 clinical trial, ILLUMINATE-204 , evaluating Toll-like receptor 9 (TLR9) agonist tilsotolimod, combined with Bristol-Myers Squibb's ( BMY -1.4% ) Yervoy (ipilimumab), in metastatic melanoma patients. More n...

Cyclacel Pharmaceuticals (NASDAQ: CYCC )  -53%  on equity offering . More news on: Cyclacel Pharmaceuticals, Inc., Summit Wireless Technologies, Inc., Sibanye Stillwater Limited, Stocks on the move, , Read more ...

– Overall response rate of 22% – – Disease control rate of 71% – – Median overall survival of 21 months – – Key topline data from ILLUMINATE-301 expected in Q1 2021 – EXTON, Pa., April 21, 2020 (GLOBE NEWSWIRE) -- Idera Pharm...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...